Modern - Blog Science Connections

109 10
6
M
E
............
fI)
fI)
'" m
:0
5
4
3
2
1
20 30
days
Fig. 2. Treatment-induced blast cell reduction in the bone marrow during high dose Thymidine therapy.
Dotted lines represent cytoreduction rates after the end of TdR infusion
one to discriminate responders and nonresponders.
The present data indicate that even
in the group of responders different blast cell
reduction rates were achieved. They ranged
from a total of 2.0 to 3.910g 10 during the 5 day
treatment period, suggesting that different
amounts of residualleukemic cells may remain
after therapy within a group of patients who all
fulfill the hematologic criteria for a complete
bm response. Quantitation of therapeutic response
may therefore result in a quantitative
assessment of remission status which may
become a determining prognostic factor for
remission duration, especially since increasing
evidence suggests that maintenance chemotherapy
has a minor or even no effect on the
duration of complete remission (Lewis et al.
1976; Omura et al. 1977; Sauter et al. 1980;
Vaughan et al. 1980).
References
Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson
BD, Melamed MR (1980) Discrimination of
human leukemia subtypes by flow cytometric analysis
of cellular DNA and RNA. Blood 55: 282-293
- Arlin Z, Gee T, Fried J, Koenigsberg E, Wolmark
N, Clarkson BD (1979) Rapid induction of remission
in acute nonlymphocytic leukemia (ANLL).
Am Assoc Cancer Res 29: 112 - Blumenreich M,
Andreeff M, Murphy ML, Young C, Clarkson
B (1980) Phase II study of mM thymidine in acute
leukemia with flow microfluorometric analysis of
drug induced kinetic alterations in the bone marrow.
Am Assoc Cancer Res 21: 179 - Donohue DM,
Gabrio BW, Finch CA (1958) Quantitative measurements
of hematopoietic cells of the marrow. J Clin
Invest 37:1564-1570 - Fauci AS (1975) Human
bone marrow lymphocytes. 1. Distribution of lymphocyte
subpopulations in the bone marrow of
normal individuals. J Clin Invest 56: 98-111 - Hid-
75